InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.27
(
-0.58%
)
Bitcoin
56,732.36
(
-2.69%
)
Post# of 252504
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

xavierprivas

Send PM Follow Ignore
Followers 6
Posts 162
Boards Moderated 0
Alias Born 09/14/2009

xavierprivas

Re: caravon post# 211389

Friday, 05/19/2017 4:23:43 AM

Friday, May 19, 2017 4:23:43 AM

Post# of 252504
Tivantinib is a failure. However ARQ 087 data is quite promising,
could get accelerated approval in 2nd line iCCA (intrahepatic Cholangiocarcinoma).

Management is questionable, given past failure but at this price
it is a decent risk/reward trade. Don't be obsessed about the past.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up